Noradrenalin Fresenius Kabi (Noradrenaline Tartrate)

Norepinephrine binds directly to alpha‑1 adrenergic receptors on vascular smooth muscle, causing vasoconstriction and raising systemic vascular resistance. It also stimulates beta‑1 receptors in the heart, modestly increasing heart rate and contractility, together elevating mean arterial pressure.

The dosing regimen for Noradrenalin Fresenius Kabi is individualized by the treating physician. The prescriber determines the infusion rate based on the patient’s hemodynamic response, target blood pressure, and clinical condition, and adjusts it as needed.

Safety data for norepinephrine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Norepinephrine is generally considered the first‑line vasopressor for septic shock because of its potent alpha‑adrenergic activity and modest beta‑1 effect, offering a balanced increase in vascular tone and cardiac output. Alternatives such as dopamine or phenylephrine may have different receptor profiles and side‑effect spectra.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

It is supplied as a sterile injectable solution for intravenous infusion. Administration is performed via a calibrated infusion pump, with the rate titrated to achieve the desired blood pressure response while continuously monitoring cardiovascular parameters.

Serious risks include severe hypertension, myocardial ischemia, tissue necrosis at the infusion site due to extravasation, and rare anaphylactic reactions. Continuous hemodynamic monitoring and prompt management of any adverse signs are essential.

Patients with known hypersensitivity to norepinephrine or any component of the formulation should not receive the product. Caution is also advised in individuals with uncontrolled hypertension, severe peripheral vascular disease, or those receiving interacting medications listed under major interactions.